Acute Tumor Lysis Syndrome after Transarterial Chemoembolization for Well-Differentiated Hepatocellular Carcinoma with Neuroendocrine Features

Onkologie ◽  
2010 ◽  
Vol 33 (10) ◽  
pp. 3-3 ◽  
Author(s):  
Kun Wang ◽  
Zhen Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Well Differentiated

scholarly journals Acute tumor lysis syndrome after transarterial chemoembolization for hepatocellular carcinoma

2008 ◽  
Vol 99 (10) ◽  
pp. 2104-2105 ◽  
Author(s):  
Hiroaki Shiba ◽  
Yuichi Ishida ◽  
Shigeki Wakiyama ◽  
Taro Sakamoto ◽  
Takeyuki Misawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis

scholarly journals Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma

2020 ◽  
Vol 14 (2) ◽  
pp. 367-372 ◽  
Author(s):  
Tsai-Hung Yen ◽  
Chung-Hsin Chang ◽  
Sz-Iuan  Shiu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Tumor Lysis Syndrome ◽  
Tumor Burden ◽  
Therapeutic Interventions ◽  
Advanced Hepatocellular Carcinoma ◽  
Large Tumor ◽  
Tumor Lysis ◽  
Advanced Hcc ◽  
First Case

Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore, we present a case of a female patient with newly diagnosed advanced HCC who developed TLS and hepatic failure after receiving combination therapy of nivolumab and sorafenib. To our knowledge, this is the first case of TLS in a patient with advanced HCC owing to combination therapy of nivolumab and sorafenib. We also reviewed the literature and summarized the characteristics of TLS in patients with advanced HCC receiving various therapeutic interventions. The overall mortality rate was 63% and regarding the management, transarterial chemoembolization (TACE) was the most common etiology. TACE-related TLS developed more rapidly than sorafenib-related TLS. Furthermore, the efficacy and safety of combination therapy of nivolumab and sorafenib should be further evaluated, and TLS should still be a concern, especially in patients with large tumor burden.

scholarly journals Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient

2015 ◽  
Vol 21 (1) ◽  
pp. 85 ◽  
Author(s):  
Jin Ok Kim ◽  
Dae Won Jun ◽  
Hye Jin Tae ◽  
Kang Nyeong Lee ◽  
Hang Lak Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Low Dose ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Carcinoma Patient

scholarly journals Tumor Lysis Syndrome in Patients With Hepatocellular Carcinoma: A Systematic Review of Published Case Reports

Cureus ◽  
2021 ◽  
Author(s):  
Jen-Wei Chou ◽  
Ken-Sheng Cheng ◽  
Trupti Akella ◽  
Chi Chan Lee ◽  
Teressa Ju
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Case Reports ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis
Sign in / Sign up

Export Citation Format

Share Document